« Zurück
Home /
Human VEGF-A ELISA Kit

Human VEGF-A ELISA Kit

ArtNr	ELH-VEGF-1
Hersteller	Raybiotech
Menge	1 Plate Kit
Quantity options	1 Plate Kit 2 Plate Kit 5 Plate Kit 1 Plate Kit 2 Plate Kit 5 Plate Kit
Kategorie	Oncology By Cell Type Carcinoma Cell Biology Cell Culture Cytokines Adenocarcinoma ELISA ELISA & Immunoassays ELISA Kits Immunoassay By Organ Lung Cancer Bladder Cancer Breast Cancer Head & Neck Cancer Heart & Blood Cancer Testicular & Prostate Cancer Renal Cancer Gastric Cancer Pancreatic Cancer Brain Cancer Nervous System Cancer Lymphatic System Cancer Uterine, Ovarian & Cervical Cancer
Typ	Elisa-Kit
Specific against	Human (Homo sapiens)
Host	Hamster - Armenian
Sensitivity	10 pg/ml
Citations	1. Steed D, Trumpower C, Duffy D, Smith C, Marshall V, et al. Amnion-derived Cellular Cytokine Solution A Physiological Combination of Cytokines for Wound Healing. Eplasty. 2008,8:e18. 2. Kung HN, Chien CL, Chau GY, Don MJ, Lu KS, Chau YP. Involvement of NO/cGMP Signaling in the Apoptotic and Anti-Angiogenic Effects of beta-Lapachone on Endothelial Cells In Vitro. J Cell Physiol. 2007,211:522–532. 3. Wang B H, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch - Eur J Physiol. 2006,452:418–427 4. Gerhardt L-C, Widdows KL, Erol MM, et al. Neocellularization and neovascularization of nanosized bioactive glass-coated decellularized trabecular bone scaffolds. J Biomed Mater Res A. 2013 Mar,101(3):827–841. 5. Lee EJ, Park H-W, Jeon H-J, et al. Potentiated therapeutic angiogenesis by primed human mesenchymal stem cells in a mouse model of hindlimb ischemia. Regen Med. 2013 May,8(3):283–293. 6. Dubois V, Delort L, Billard H, et al. Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies? PLoS ONE. 2013,8(3):e58541. doi:10.1371/journal.pone.0058541 7. Chen CJ, Wang JC, Zhao EY, et al. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials. 2013,34(21):5303–5316. 8. Dubois V, Delort L, Billard H, et al. Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies? PLoS ONE. 2013,8(3):e58541. 9. Etulain J, Fondevila C, Negrotto S, Schattner M. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol. 2013 May 28. doi: 10.1111/bph.12250. [Epub ahead of print] 10. Navid F, Baker SD, McCarville B, et al. Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clin Cancer Res. 2013,19(1):236–246. 11. Khan R, Sharma M, Kumar L, et al. Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma. Ann Hematol. 2013 Jan,92(1):101–109. 12. Yalçindag A, Gedik-Oguz Y, Yalçindag FN. The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2013 Jul,251(7):1807–1812. 13. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma 14. Mondal LK, Choudhury S, Paine SK, et al. Anaerobic Glycolysis is the Centre of Different Biochemical Disarrays Associated with the Onset of Diabetic Retinopathy. J Evol Med Dent Sci. 2013 Apr 8,(924). 15. Sivaprasad S, Govardhan B, Harithakrishna R, et al. Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma. Pancreatology. 2013 May,13(3):267–272. 16. Galecki P, Galecka E, Maes M, et al. Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development. Prog Neuropsychopharmacol Biol Psychiat. 2013 May 11. 17. Guerra Dore CMP, Faustino Alves MGC, Santos ND, et al. Antiangiogenic activity and direct antitumor effect from a sulfated polysaccharide isolated from seaweed. Microvasc Res. 2013 Jul,88:12–18. 18. Elsayh KI, Zahran AM, El-Abaseri TB, et al. Hypoxia Biomarkers, Oxidative Stress, and Circulating Microparticles in Pediatric Patients With Thalassemia in Upper Egypt. Clin Appl Thromb Hemost. 2013 Jan 11, [Epub online before print] doi:10.1177/1076029612472552. 19. Wang Z, Humphries B, Xiao H, et al. Epithelial to mesenchymal transition in arsenic-transformed cells promotes angiogenesis through activating beta-catenin-vascular endothelial growth factor pathway. Toxicol Appl Pharmacol. 2013 Apr 30,271(1):20–29. 20. Hartwich J, Orr WS, Ng CY, et al. HIF-1alpha activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts. J. Pediatr. Surg. 2013 Jan,48(1):39–46. 21. Hartwich J, Orr WS, Ng CY, et al. HIF-1alpha activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts. J. Pediatr. Surg. 2013 Jan,48(1):39–46. 22. Okano, Teruo, Tetsutaro Kikuchi, and Tatsuya Shimizu. "Automatic Fabrication of 3-dimensional Tissues Using Cell Sheet Manipulator Technique." Biomaterials. ScienceDirect, Mar. 2014. Web. 23. Vizio, Barbara, Fiorella Biasi, and Giuseppe Poli. "Pancreatic-carcinoma-cell-derived Pro-angiogenic Factors Can Induce Endothelial-cell Differentiation of a Subset of Circulating CD34+ Progenitors." Journal of Translational Medicine. NCBI, 17 Dec. 2013. Web. 24. Chen, Yun-Ju, Yu-Jen Cheng, Amos C. Hung, and Yang-Chang Wu. "The Synthetic Flavonoid WYC02-9 Inhibits Cervical Cancer Cell Migration/invasion and Angiogenesis via MAPK14 Signaling." Gynecologic Oncology. ScienceDirect, Dec. 2013. Web. 25. Bhuvaneswari R, Gan Y, Yee K, Soo K,Olivo M. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med. 2007,20:421-428. 26. Koob T., Lim J., Massee M., Zabek N., Rennet R., Gurtner G., Li W. Angiogenic properties of dehydrated human amnion/chorion allografts. Vascular Cell 2014,6:10 doi:10.1186/2045-824X-6-10 [Epub Ahead of Print] therapeutic potential for soft tissue repair and regeneration 27. Etulain J., Negrotto S., Tribulatti M., Croci D., Carabelli J., et al. Control of Angiogenesis by Galectins Involves the Release of Platelet-Derived Proangiogenic Factors. PLOS One, Published: April 30, 2014 DOI: 10.1371/journal.pone.0096402 [Epub Ahead of Print] 28. Matas-Cespedes A., Rodriguez V., Kalka S. et al. Disruption of follicular dendritic cells - follicular lymphoma crosstalk by the pan-PI3K inhibitor BKM120 (buparlisib). Clinical Cancer Research. Published online May 5 2014 doi: 10.1158/1078-0432.CCR-14-0154 [Epub ahead of print] 29. Grigore Alexandra G., Bapi S., Ben F., Aldo B., Rainer D., Behavior of Encapsulated MG-63 Cells in RGD and Gelatine-Modified Alginate Hydrogels. Tissue Engineering Part A. Online ahead of print May 9, 2014. doi:10.1089/ten.tea.2013.0416. [Epub ahead of print] 30. Hartwich J., Orr S., Ng C., Spence Y., Morton C., DavidoffA. HIF-1[alpha] activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts. Journal of Pediatric Surgery Volume 48, Issue 1 , Pages 39-46, January 2013 31. Chen C., Wang J., Zhao E., Gao L., Feng Q., Liu X., et al. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials 34 (2013) 5303-5316 32. Moa D., Zhang Y., Lu H., Zhang H. Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment. Tumor Biology, 2014 May, Epub Ahead of Print. DOI 10.1007/s13277-014-2095-6 33. Platt, DH et al. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic. Biol. Med. Volume 39, Issue 10, Pages 1353-61, Nov 2005 34. Chen D., et al. Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer. Genes Cancer. May 2014, 5(5-6): 212–225 35. Zaytseva Y., et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis vol.35 no.6 pp.1341–1351, 2014. doi:10.1093/carcin/bgu042 36. Skriver K., et al. Acute exercise improves motor memory: Exploring potential biomarkers. Neurobiology of Learning and Memory 2014, epub ahead of print. 37. Lima AC., et al. Fast and Mild Strategy, Using Superhydrophobic Surfaces, to Produce Collagen/Platelet Lysate Gel Beads for Skin Regeneration. Stem Cell Rev and Rep, Aug 2014. epub ahead of print. DOI 10.1007/s12015-014-9548-6 38. Chen B., et al. Molecular regulation of cervical cancer growth and invasion by VEGFa. Tumor Biology 2014 Aug, Epub Ahead of Print. DOI 10.1007/s13277-014-2463-2 39. Arnold C., et al. Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis. Oncoscience 2014, Vol.1, No.8 40. Diaz-Gomez L., et al. Random and Aligned PLLA : PRGF Electrospun Scaffolds for Regenerative Medicine. Journal of Applied Polymer Science August 2014, epub ahead of print. DOI: 10.1002/app.41372 41. Koob T., et al. Cytokines in single layer amnion allografts compared to multilayer amnion/chorion allografts for wound healing. Journal of Biomedical Materials Research Part B: Applied Biomaterials. Aug 2014, epub ahead of print. DOI: 10.1002/jbm.b.33265 42. Bigalke C., et al. VEGF-releasing suture material for enhancement of vascularization: 4 Development, in vitro and in vivo study. Acta Biomaterialia 7 September 2014, DOI: 10.1016/j.actbio.2014.09.002 43. Gon J., et al. Interplay of VEGFa and MMP2 regulates invasion of glioblastoma. Tumor Biology, Sept 2014, epub ahead of print. DOI 10.1007/s13277-014-2438-3 44. Perez-Garcia JL., et al. Identification of TNF-a and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. British Journal of Cancer (2009) 101, 1876 – 1883 45. Yang H, Wang B, Wang T, Xu L, He C, et al. (2014) Toll-Like Receptor 4 Prompts Human Breast Cancer Cells Invasiveness via Lipopolysaccharide Stimulation and Is Overexpressed in Patients with Lymph Node Metastasis. PLoS ONE 9(10): e109980. doi:10.1371/journal.pone.0109980
ECLASS 10.1	32160605
ECLASS 11.0	32160605
UNSPSC	41116126
Similar products	VEGF-A
Versandbedingung	Gekühlt
Lieferbar
Specificity	This ELISA kit shows no cross-reactivity with any of the cytokines tested: Human Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, I-309, IP-10, G-CSF,
Manufacturer - Category	ELISA Kits\|Sandwich ELISA
Manufacturer - Targets	VEGF-A
Shipping Temperature	Blue ice
Storage Conditions	?-20°C
Description	RayBio® Human VEGF-A ELISA Kit for cell culture supernatants, plasma, serum, and lysate samples. Lead time: Typically ships within 1-2 business days. No Friday shipments.
Compatible Sample Types	Cell Culture Supernatants, Plasma, Serum, Urine
Design Principle	Sandwich-based
Method of Detection	Colorimetric
Solid Support	96-well Microplate
Kit Components	Pre-Coated 96-well Strip Microplate Wash Buffer Stop Solution Assay Diluent(s) Lyophilized Standard Biotinylated Detection Antibody Streptavidin-Conjugated HRP TMB One-Step Substrate
Other Materials Required	Distilled or deionized water Precision pipettes to deliver 2 ul to 1 ul volumes Adjustable 1-25 ul pipettes for reagent preparation 100 ul and 1 liter graduated cylinders Tubes to prepare standard and sample dilutions Absorbent paper Microplate reader capable of measuring absorbance at 450nm Log-log graph paper or computer and software for ELISA data analysis
Protocol Outline	Prepare all reagents, samples and standards as instructed in the manual. Add 100 ul of standard or sample to each well. Incubate 2.5 h at RT or O/N at 4C. Add 100 ul of prepared biotin antibody to each well. Incubate 1 h at RT. Add 100 ul of prepared Streptavidin solution to each well. Incubate 45 min at RT. Add 100 ul of TMB One-Step Substrate Reagent to each well. Incubate 30 min at RT. Add 50 ul of Stop Solution to each well. Read at 450 nm immediately.
Product Features	Strip plates and additional reagents allow for use in multiple experiments Quantitative protein detection Establishes normal range The best products for confirmation of antibody array data
Result Output	Quantitative
UNSPSC Code	41116158
Manufacturer - Specificity	This ELISA kit shows no cross-reactivity with any of the cytokines tested: Human Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, I-309, IP-10, G-CSF, GM-CSF, IFN-gamma, Leptin, MCP-1, MCP-2, MCP-3, MDC, MIP-1 alpha, MIP-1 beta, MIP-1 delta, PARC, PDGF, RANTES, SCF, TARC, TGF-beta, TIMP-1, TIMP-2, TNF-alpha, TNF-beta, TPO.
Recommended Dilution	2-5 fold

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

ELH-VEGF-1.pdf

ELH-VEGF-1-datasheet.pdf

ELH-VEGF-1-safety-datasheet.pdf